Short Interest in Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Expands By 59.0%

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 185,700 shares, an increase of 59.0% from the February 28th total of 116,800 shares. Based on an average daily trading volume, of 2,030,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 3.0% of the shares of the company are short sold.

Protagenic Therapeutics Stock Down 10.0 %

Shares of PTIX traded down $0.03 during mid-day trading on Friday, reaching $0.23. The company had a trading volume of 70,972 shares, compared to its average volume of 638,314. The stock has a market capitalization of $1.63 million, a P/E ratio of -0.18 and a beta of 0.43. Protagenic Therapeutics has a 52-week low of $0.23 and a 52-week high of $1.87. The stock has a 50 day moving average of $0.31 and a two-hundred day moving average of $0.50.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.